Introduction
============

Gastric cancer (GC) is one of the most common malignancies and ranks the second cause of cancer deaths worldwide.[@b1-ott-10-4321] Over the last 10 years, diagnostic capabilities and therapeutic methods have been developed, but the prognosis for GC patients still remains poor, especially in those in the advanced stage.[@b2-ott-10-4321] Tumor biomarkers reflect the pathological characteristics of tumor cells; therefore, they often have diagnostic significance or prognostic value. The expression level of many prognostic biomarkers is associated with patient survival and can be particularly valuable in terms of guiding the clinical treatment of patients; some prognostic biomarkers also have potential as novel therapeutic targets. Therefore, novel prognostic biomarkers and therapeutic targets need be identified for the management of GC.

Ki-67, as a well-characterized nuclear protein, is encoded by the *MKI-67* gene that is associated with the transcription of ribosomal RNA and cell proliferation and is involved in the development of tumor.[@b3-ott-10-4321],[@b4-ott-10-4321] Some studies reported that Ki-67 is only expressed in the G1, S, and G2 stages of the cell cycle during mitosis, but not the G0 stage; hence, Ki-67 usually is regarded as a valuable biomarker of cell growth and proliferation.[@b5-ott-10-4321],[@b6-ott-10-4321] Many retrospective articles have reported that the high level of Ki-67 is associated with poor prognosis in patients with GC.[@b7-ott-10-4321]--[@b19-ott-10-4321] However, the results of other articles are inconclusive and no consensus has been reached, and some studies reported that Ki-67 expression is prognostically irrelevant in GC patients.[@b20-ott-10-4321]--[@b23-ott-10-4321] Therefore, it is necessary to evaluate the prognostic and clinicopathological value of Ki-67 expression in GC. Accordingly, we performed a systematic review and meta-analysis to evaluate the prognostic value of Ki-67 quantitatively and explore the associations of Ki-67 with the clinicopathological features of GC.

Methods
=======

Search strategy
---------------

We performed a thorough search for available literature in electronic databases of PubMed, EMBASE and Web of Science until May 2017. The search terms "Ki-67 AND (GC OR gastric neoplasm OR gastric carcinoma OR gastric malignancy)" were applied, and we initially identified 783 entries for further examination. The references cited by the primary studies were also reviewed in this search strategy. The most recent or larger sample size studies were selected when duplicated data were published.

Selection criteria
------------------

The 22 eligible studies had to meet the following criteria: 1) studies in which expression of Ki-67 in the primary GC tissue was evaluated by immunohistochemistry (IHC); 2) studies that investigated the association between Ki-67 expression and prognosis of patients (overall survival \[OS\]), or studies that described the correlation between Ki-67 and clinicopathological features in GC; and 3) only published studies written in English. The exclusion criteria were as follows: 1) studies that were reviews, letters or conference papers; 2) studies that were not performed in humans; and 3) articles that failed to report sufficient data for determining desired meta-analysis outcomes. All evaluations were separately undertaken by two authors to guarantee the precision of the selection process.

Data extraction
---------------

All candidate articles were carefully assessed by two independent reviewers (Gang Liu and Disheng Xiong) for possible inclusion; any disagreements were resolved by discussion between the two reviewers or consultation with a third reviewer (Zhengjie Huang). The following information was captured from all included studies: first author, country, publication year, number of patients, patient age and gender, positive expression rate of Ki-67, detection method, cutoff value, hazard ratios (HRs) for OS and their 95% confidence intervals (CIs) and clinicopathological features. HRs and 95% CIs were directly extracted from articles or estimated from Kaplan--Meier survival curves by the open digitizing program (Engauge Digitizer) and Tierney's methods.[@b20-ott-10-4321]

Statistical analysis
--------------------

The meta-analysis was performed using Review Manager version 5.3 (Cochrane Collaboration, Oxford, UK). Heterogeneity across eligible studies was evaluated by Cochran's *Q* test and *I*^2^ test (a *P*-value \<0.10 for the *Q*-test or *I*^2^ \>50% represented statistically significant heterogeneity). The fixed-effects model or random-effects model was used depending on the aforementioned heterogeneity analysis. HRs and 95% CIs were applied to estimate the impact of Ki-67 on OS, while ORs and 95% CIs were used to assess the association between Ki-67 expression and clinicopathological characteristics in GC. Potential publication bias was assessed using Begg's funnel plot and Egger's test. All of the generated *P*-values \<0.05 were defined as statistically significant.

Results
=======

Search results
--------------

A flowchart of the study selection process is shown in [Figure 1](#f1-ott-10-4321){ref-type="fig"}. The search strategy generated 783 articles, of which 164 were considered potentially valuable after reading titles and abstracts. Then, the full text was retrieved for detailed evaluation and 37 were subsequently excluded for various reasons, including not prognostic or clinicopathological study. Eventually, 22 of the studies as of May 2017 (with a total of 3,825 patients) satisfied the criteria for this meta-analysis.[@b7-ott-10-4321]--[@b19-ott-10-4321]

Characteristics of studies
--------------------------

The main characteristics of the 22 studies are summarized in [Table 1](#t1-ott-10-4321){ref-type="table"}. The 22 eligible studies were published between 2006 and 2017. Of them, 13 studies originated from China, three were from Korea, one was from Greece, one was from Poland, one was from Japan, one was from Tunisia, one was from Germany, and one was from Egypt. Among the studies, 18 were performed to analyze OS. Hazard ratio (HR) and 95% CI data were extracted directly from the 14 studies and estimated by Kaplan--Meier survival curves in four studies. Various clinicopathological data were reported in 22 studies (age in eight studies, gender in eight studies, lymph nodes metastasis in nine studies, TNM stage in seven studies, tumor size in six studies and histological differentiation in eight studies).

Meta-analysis
-------------

Eighteen studies were included in the meta-analysis of OS. A random-effects model utilized to calculate the pooled HR and 95% CI on account of the heterogeneity test reported a *P*\<0.00001 and an *I*^2^ value of 80.0%. The results suggested that Ki-67 overexpression was associated with poor OS of GC (HR =1.58, 95% CI =1.31--1.91, *P*\<0.00001) ([Figure 2](#f2-ott-10-4321){ref-type="fig"}).

As shown in [Table 2](#t2-ott-10-4321){ref-type="table"}, the correlation between Ki-67 overexpression and age, gender, lymph node metastasis, tumor size, tumor TNM stage and histological differentiation was also explored in our meta-analysis ([Figures 3](#f3-ott-10-4321){ref-type="fig"}[](#f4-ott-10-4321){ref-type="fig"}[](#f5-ott-10-4321){ref-type="fig"}[](#f6-ott-10-4321){ref-type="fig"}[](#f7-ott-10-4321){ref-type="fig"}--[8](#f8-ott-10-4321){ref-type="fig"}). According to the results of evidence synthesis, we found that Ki-67 overexpression significantly correlated with age (OR =1.44, 95% CI \[1.19, 1.75\]) ([Figure 3](#f3-ott-10-4321){ref-type="fig"}), lymph node metastasis (OR =1.49, 95% CI \[1.20, 1.84\]) ([Figure 5](#f5-ott-10-4321){ref-type="fig"}), tumor size (OR =1.27, 95% CI \[1.24, 1.68\]) ([Figure 6](#f6-ott-10-4321){ref-type="fig"}), tumor TNM stage (OR =2.28, 95% CI \[1.66, 3.12\]) ([Figure 7](#f7-ott-10-4321){ref-type="fig"}) and histological differentiation (OR =1.76, 95% CI \[1.02, 3.03\]) ([Figure 8](#f8-ott-10-4321){ref-type="fig"}). However, no statistical differences existed in gender (OR =1.00, 95% CI \[0.67, 1.25\]) ([Figure 4](#f4-ott-10-4321){ref-type="fig"}).

Due to the heterogeneity, we performed the subgroup analyses, as is shown in [Table 3](#t3-ott-10-4321){ref-type="table"}, by stratifying the combined data according to ethnicity (Asian vs Caucasian), cutoff of staining (\<50% vs ≥50%) and number of patients (\<100 vs ≥100).

Publication bias
----------------

As shown in [Figure 9](#f9-ott-10-4321){ref-type="fig"}, Begg's and Egger's tests, as well as funnel plots, were conducted to estimate publication bias in the present meta-analysis. The funnel plots indicated that the included studies had no evident asymmetry. These findings suggested that significant publication bias did not exist in our meta-analysis.

Discussion
==========

In recent years, despite improvement in diagnosis and therapy, GC is still characterized by late clinical presentation, rapid progression and poor survival. Considering the high morbidity and mortality of GC, researchers have been dedicated in identifying available new prognostic markers to achieve better clinical decision making regarding therapy and outcomes, in past decades. As far as we know, Ki-67 has been declared as a predictor of cell proliferation, malignant potential and recurrence of cancer. Ki-67 expression in GC is controversial. For example, a number of retrospective articles have reported that high level of Ki-67 is associated with poor prognosis in patients with GC. However, some studies suggested that Ki-67 overexpression is prognostically irrelevant in GC patients. Therefore, we performed a systematic review and meta-analysis to evaluate the prognostic value of Ki-67 and explore the associations of Ki-67 with the clinicopathological features of GC.

In our study, a combined analysis of 22 eligible clinical studies revealed a critical role of Ki-67 overexpression in GC progression and prognosis. The meta-analysis results suggested that GC patients with low Ki-67 expression showed better OS than those with high Ki-67 expression. In addition, we performed meta-analyses to determine the relationship between Ki-67 overexpression and the clinical features of GC, and correlations between Ki-67 upregulation and age, gender, lymph node metastasis, tumor size, TNM stage and histological differentiation were observed. Finally, we revealed that high level of Ki-67 was significantly associated with high risk of age, lymph node metastasis, tumor size, tumor TNM stage and histological differentiation. However, no statistical differences existed in gender. Although with highly significant heterogeneity, this new result also had statistical significance, illustrating that high Ki-67 expression was significantly associated with poor OS of patients with GC.

As we all know, Ki-67 is an antigen that corresponds to a nuclear non-histone protein expressed by cells in the proliferative phases G1, G2, M, and S. Scholzen and Gerdes have reported that quiescent cells in the G0 phase do not express the Ki-67 antigen, making Ki-67 a good marker to detect the cell proliferative fraction.[@b24-ott-10-4321] Many studies have shown that Ki-67 expression is a valuable independent prognostic predictor for the survival of patients with GC,[@b25-ott-10-4321]--[@b27-ott-10-4321] which is consistent with the present study. The detection of expression of Ki-67 in GC provides prognostic information for patients with the disease.[@b6-ott-10-4321],[@b28-ott-10-4321],[@b29-ott-10-4321] In the present meta-analysis, the overexpression of Ki-67 is significantly increased in patients with clinical grade, tumor TNM stage, metastases occurrence and poor prognosis. This may help us to use these markers as a meaningful prognostic and predictive biomarker in each patient with GC.

In summary, the present meta-analysis shows that Ki-67 overexpression can predict an unfavorable prognosis of GC patients. Our results also indicate an association of Ki-67 upregulation with clinicopathological features such as age, lymph node metastasis, tumor size, tumor TNM stage and histological differentiation. More multicenter and prospective studies are needed to clarify the clinical relevance and precise molecular explanation for the abnormal expression of Ki-67.
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![Flow diagram of the meta-analysis process.](ott-10-4321Fig1){#f1-ott-10-4321}

![HRs and 95% CIs in studies assessing the relationship between Ki-67 expression and OS.\
**Abbreviations:** CI, confidence interval; HR, hazard ratio; IV, inverse variance; OS, overall survival; SE, standard error.](ott-10-4321Fig2){#f2-ott-10-4321}

![Forest plot of studies evaluating the association between Ki-67 and clinical parameters (older vs younger age) in gastric cancer with fixed-effects model.\
**Abbreviations:** CI, confidence interval; M--H, Mantel--Haenszel.](ott-10-4321Fig3){#f3-ott-10-4321}

![Forest plot of studies evaluating the association between Ki-67 and clinical parameters (male vs female gender) in gastric cancer with fixed-effects model.\
**Abbreviations:** CI, confidence interval; M--H, Mantel--Haenszel.](ott-10-4321Fig4){#f4-ott-10-4321}

![Forest plot of studies evaluating the association between Ki-67 and clinical parameters (N+ vs N− lymph node metastasis) in gastric cancer with fixed-effects model.\
**Abbreviations:** CI, confidence interval; LNM, lymph node metastasis; M--H, Mantel--Haenszel.](ott-10-4321Fig5){#f5-ott-10-4321}

![Forest plot of studies evaluating the association between Ki-67 and clinical parameters (large vs small tumor size) in gastric cancer with fixed-effects model.\
**Abbreviations:** CI, confidence interval; M--H, Mantel--Haenszel.](ott-10-4321Fig6){#f6-ott-10-4321}

![Forest plot of studies evaluating the association between Ki-67 and clinical parameters (III+IV vs I+II TNM stage) in gastric cancer with fixed-effects model.\
**Abbreviations:** CI, confidence interval; M--H, Mantel--Haenszel.](ott-10-4321Fig7){#f7-ott-10-4321}

![Forest plot of studies evaluating the association between Ki-67 and clinical parameters (low vs well/moderate differentiation) in gastric cancer with random-effects model.\
**Abbreviations:** CI, confidence interval; M--H, Mantel--Haenszel.](ott-10-4321Fig8){#f8-ott-10-4321}

![Funnel plot and Begg's and Egger's tests for evaluation of potential publication bias.\
**Abbreviations:** HR, hazard ratio; SE, standard error.](ott-10-4321Fig9){#f9-ott-10-4321}

###### 

Characteristics of the included studies

  Reference                                  Country   Case number   Gender (m/f)   Age (y)                  Detection method (cutoff)   Increased Ki-67, n (%)   Survival analysis   HR (95% CI)         HR (obtained)
  ------------------------------------------ --------- ------------- -------------- ------------------------ --------------------------- ------------------------ ------------------- ------------------- ---------------
  Joo et al (2006)[@b25-ott-10-4321]         Korea     118           84/35          52/67 (\<59 y/≥59 y)     IHC (strong staining)       62 (52.5)                NR                  NR                  NR
  Chen et al (2008)[@b7-ott-10-4321]         China     86            57/29          Mean 57.6                IHC (\>10%)                 64 (74.4)                OS                  1.62 (1.45--1.81)   Curve
  Tsamandas et al (2009)[@b8-ott-10-4321]    Greece    110           71/39          Mean 66.0                IHC (\>5%)                  15 (13.6)                OS                  2.15 (1.07--4.32)   Direct
  Czyzewska et al (2009)[@b19-ott-10-4321]   Poland    100           67/33          34/65 (\<60 y/≥60 y)     IHC (\>50%)                 37 (37.0)                OS                  1.12 (0.86--1.46)   Curve
  Lee et al (2010)[@b20-ott-10-4321]         Korea     245           171/74         202/43 (≤65 y/\>65 y)    IHC (\>10%)                 164 (66.9)               OS                  0.56 (0.38--0.83)   Direct
  Zhao et al (2010)[@b26-ott-10-4321]        China     316           NR             Mean 58.1                IHC (score ≥5)              196 (62.0)               NR                  NR                  NR
  Yu et al (2012)[@b9-ott-10-4321]           China     315           165/150        177/138 (\<60 y/≥60 y)   IHC (\>50%)                 76 (24.1)                OS                  1.75 (1.13--2.34)   Direct
  Xiao et al (2013)[@b21-ott-10-4321]        Japan     431           301/130        Mean 66.4                IHC (score ≥1)              362 (84.0)               OS                  0.98 (0.82--1.17)   Direct
  Kang et al (2013)[@b22-ott-10-4321]        Korea     184           123/61         Mean 61.0                IHC (\>10%)                 100 (54.3)               OS                  0.18 (0.03--1.06)   Direct
  He et al (2013)[@b22-ott-10-4321]          China     166           113/53         43/38 (\<60 y/≥60 y)     IHC (\>25%)                 94 (56.0)                OS                  1.85 (1.30--2.63)   Direct
  Ayed et al (2014)[@b11-ott-10-4321]        Tunisia   54            34/20          21/33 (≤50 y/\>50 y)     IHC (\>5%)                  11 (20.4)                OS                  4.17 (1.08--16.1)   Direct
  Ezziddin et al (2014)[@b12-ott-10-4321]    Germany   74            42/32          Mean 62.5                IHC (\>10%)                 14 (18.9)                OS                  3.10 (1.40--6.90)   Direct
  Yang et al (2014)[@b14-ott-10-4321]        China     159           118/41         Mean 58.0                IHC (\>30%)                 115 (72.3)               OS                  1.84 (1.21--2.80)   Curve
  Zhou et al (2015)[@b27-ott-10-4321]        China     40            28/12          18/22 (≤60 y/\>60 y)     IHC (\>5%)                  28 (70.0)                NR                  NR                  NR
  Li et al (2015)[@b15-ott-10-4321]          China     69            51/18          Mean 55.0                IHC (\>50%)                 42 (60.9)                OS                  1.62 (1.28--2.05)   Curve
  Yang et al (2015)[@b13-ott-10-4321]        China     161           108/53         NR                       IHC (\>50%)                 98 (60.9)                OS                  2.50 (1.34--4.65)   Direct
  Deng et al (2016)[@b23-ott-10-4321]        China     62            48/14          Mean 63.4                NR                          28 (45.2)                OS                  1.56 (0.72--3.38)   Direct
  Huang et al (2016)[@b17-ott-10-4321]       China     693           515/178        Mean 60.3                IHC (\>50%)                 335 (48.3)               OS                  1.46 (1.22--1.75)   Direct
  Wang et al (2016)[@b17-ott-10-4321]        China     173           117/56         NR                       IHC (\>50%)                 114 (65.9)               OS                  2.97 (1.94--4.55)   Direct
  Zhu et al (2016)[@b18-ott-10-4321]         China     150           100/50         NR                       IHC (\>50%)                 89 (59.3)                OS                  2.93 (1.52--5.65)   Direct
  Badary et al (2017)[@b28-ott-10-4321]      Egypt     42            26/16          Mean 53.0                IHC (\>10%)                 22 (52.4)                NR                  NR                  NR
  Zhang et al (2017)[@b24-ott-10-4321]       China     77            44/33          41/36 (≤48 y/\>48 y)     IHC (\>5%)                  48 (62.3)                OS                  1.43 (0.67--3.04)   Direct

**Note:** Age data shown as mean or number of patients per the age ranges specified in parentheses.

**Abbreviations:** CI, confidence interval; f, female; HR, hazard ratio; IHC, immunohistochemistry; m, male; NR, not reported; OS, overall survival; y, years.

###### 

Association of Ki-67 expression and clinicopathological parameters

  Clinicopathological parameters           Number of studies   Number of patients   OR (95% CI)         *P*-value   Heterogeneity   
  ---------------------------------------- ------------------- -------------------- ------------------- ----------- --------------- --------
  Age (older vs younger)                   8                   1,868                1.44 (1.19--1.75)   0.0002      0               0.43
  Gender (male vs female)                  8                   1,578                1.00 (0.76--1.25)   0.98        0               0.54
  Lymph node metastasis (N+ vs N−)         9                   1,858                1.49 (1.20--1.84)   0.0002      50              0.04
  Tumor size (large vs small)              6                   1,718                1.37 (1.12--1.68)   0.002       36              0.17
  TNM stage (III+IV vs I+II)               7                   773                  2.28 (1.66--3.12)   \<0.00001   46              0.09
  Differentiation (low vs well/moderate)   8                   735                  1.76 (1.02--3.03)   0.04        72              0.0007

**Abbreviations:** CI, confidence interval; N, node; OR, odds ratio.

###### 

Subgroup analysis of pooled HR for gastric cancer patients with Ki-67 overexpression

  Subgroup             Studies   Pooled HR   95% CI       *P*-value   Model    Heterogeneity *I*^2^ (%)   *P*-value
  -------------------- --------- ----------- ------------ ----------- -------- -------------------------- -----------
  Ethnicity                                                                                               
   Asian               14        1.54        1.25--1.89   \<0.0001    Random   82                         \<0.00001
   Caucasian           4         2.04        1.08--3.86   0.03        Random   71                         0.01
  Cutoff of staining                                                                                      
   \<50%               10        1.52        1.09--2.12   0.01        Random   78                         \<0.00001
   ≥50%                7         1.78        1.40--2.27   \<0.0001    Random   72                         0.002
  Number of patients                                                                                      
   \<100               6         1.64        1.49--1.81   \<0.00001   Fixed    0                          0.48
   ≥100                12        1.51        1.15--1.97   0.003       Random   84                         \<0.00001

**Abbreviations:** HR, hazard ratio; CI, confidence interval.
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